NPS MedicineWise has summarised three new drugs that may cross your pharmacy store counter this month: benralizumab for asthma, dulaglutide for type 2 diabetes and trifluridine/tipiracil for colorectal cancer.
The summaries are published in the NPS Australian Prescriber.
Fasenra (benralizumab) by AstraZeneca is a humanised IgG1 monoclonal antibody that presents in a pre-filled syringe.
Trulicity (dulaglutide) from Eli Lilly is a genetically engineered protein and is marketed in pre-filled pens and syringes, while Lonsurf (trifluridine/tipiracil) by Servier is a fixed-dose combination tablet therapy and is indicated for people with metastatic colorectal cancer under specific conditions.
See more details at nps.org.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Sep 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Sep 18
